New hope for tough leukemia: drug cocktail targets resistant cancer
NCT ID NCT05222984
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a three-drug combination (navitoclax, venetoclax, and decitabine) in adults and teens with acute myeloid leukemia that returned or didn't respond to previous treatment. The goal is to find the safest dose and see if the combo can shrink or control the cancer. About 17 participants will be enrolled at City of Hope.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to wake up immune system against Hard-to-Treat leukemia
- New drug combo aims to outsmart resistant leukemia
- Gentler chemo approach shows promise for tough blood cancers in older patients
- Selective immune cell removal may tame transplant complications
- Promising combo for IDH1 leukemia hits early snag – trial stopped
- Engineered immune cells take aim at Hard-to-Treat leukemia